Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all
Page 1
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, Manfrini M, McNamara J, Robertson DS, Stokmaier D, Wendt JK, Winthrop KL, Traboulsee A. Bar-Or A, et al. Among authors: chognot c. Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29. Neurology. 2020. PMID: 32727835 Free PMC article. Clinical Trial.
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Henry RR, et al. Among authors: chognot c. Lancet. 2009 Jul 11;374(9684):126-35. doi: 10.1016/S0140-6736(09)60870-9. Epub 2009 Jun 8. Lancet. 2009. PMID: 19515415 Clinical Trial.